[
  {
    "ts": null,
    "headline": "Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug",
    "summary": "Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug Kisunla, blocking access for patients seeking treatment under the...",
    "url": "https://finnhub.io/api/news?id=50eebf950cba06c42fdea6547b8c49248a5feb4711054fc929e0a50a2029df75",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750273335,
      "headline": "Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug",
      "id": 135374639,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug Kisunla, blocking access for patients seeking treatment under the...",
      "url": "https://finnhub.io/api/news?id=50eebf950cba06c42fdea6547b8c49248a5feb4711054fc929e0a50a2029df75"
    }
  },
  {
    "ts": null,
    "headline": "Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results",
    "summary": "Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a weight-loss drug trial.",
    "url": "https://finnhub.io/api/news?id=e9f17bc16490d5af00cf51972e9d70aefbffbe3cf8adc06729ae775cb3195e61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750261233,
      "headline": "Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results",
      "id": 135370751,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a weight-loss drug trial.",
      "url": "https://finnhub.io/api/news?id=e9f17bc16490d5af00cf51972e9d70aefbffbe3cf8adc06729ae775cb3195e61"
    }
  },
  {
    "ts": null,
    "headline": "Indexes briefly add to gains after Fed statement, trade volatile",
    "summary": "* Concerns about Middle East persist * Iran leader rejects Trump's demand for surrender * Indexes up: Dow 0.3%, S&P 500 0.3%, Nasdaq 0.4% ...",
    "url": "https://finnhub.io/api/news?id=55a78f64468a254205014d1823090c826df091f7ff847ecd9aae2027e8cc5c32",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750257131,
      "headline": "Indexes briefly add to gains after Fed statement, trade volatile",
      "id": 135372884,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "* Concerns about Middle East persist * Iran leader rejects Trump's demand for surrender * Indexes up: Dow 0.3%, S&P 500 0.3%, Nasdaq 0.4% ...",
      "url": "https://finnhub.io/api/news?id=55a78f64468a254205014d1823090c826df091f7ff847ecd9aae2027e8cc5c32"
    }
  },
  {
    "ts": null,
    "headline": "GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?",
    "summary": "GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.",
    "url": "https://finnhub.io/api/news?id=547e450da5dab1f49048cfe0f806d54a87f7c3d641b4306da95706f540275b12",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750256520,
      "headline": "GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?",
      "id": 135366748,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.",
      "url": "https://finnhub.io/api/news?id=547e450da5dab1f49048cfe0f806d54a87f7c3d641b4306da95706f540275b12"
    }
  },
  {
    "ts": null,
    "headline": "How a Solar Factory in the Heartland Sees the ‘Big Beautiful Bill’",
    "summary": "How a Solar Factory in the Heartland Sees the ‘Big Beautiful Bill’",
    "url": "https://finnhub.io/api/news?id=02585e0565e97ce8d93d0f4a327476c473e7a6a7da29e6f41e39cbe4b43bdc59",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750255680,
      "headline": "How a Solar Factory in the Heartland Sees the ‘Big Beautiful Bill’",
      "id": 135389017,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "How a Solar Factory in the Heartland Sees the ‘Big Beautiful Bill’",
      "url": "https://finnhub.io/api/news?id=02585e0565e97ce8d93d0f4a327476c473e7a6a7da29e6f41e39cbe4b43bdc59"
    }
  },
  {
    "ts": null,
    "headline": "Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.",
    "summary": "Eli Lilly shares have soared in value in recent years due to the success of its GLP-1 drugs.  Viking Therapeutics and Altimmune have exciting GLP-1 products entering phase 3 trials.  Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years, thanks in large part to the success of its incredibly successful GLP-1 agonist drugs, which help patients with diabetes and weight loss.",
    "url": "https://finnhub.io/api/news?id=556f32787aa86cb4d559e489c62e83e4dcc18bacf2f66ffb1127a133ff5545a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750254780,
      "headline": "Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.",
      "id": 135358095,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly shares have soared in value in recent years due to the success of its GLP-1 drugs.  Viking Therapeutics and Altimmune have exciting GLP-1 products entering phase 3 trials.  Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years, thanks in large part to the success of its incredibly successful GLP-1 agonist drugs, which help patients with diabetes and weight loss.",
      "url": "https://finnhub.io/api/news?id=556f32787aa86cb4d559e489c62e83e4dcc18bacf2f66ffb1127a133ff5545a2"
    }
  },
  {
    "ts": null,
    "headline": "Gene-Editing Stocks Gain on LLY-VERV Deal Announcement",
    "summary": "LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.",
    "url": "https://finnhub.io/api/news?id=0e5e497a13ebc0a5849ce40d27b13c4116ceec96870181d53d6d43407edb73c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750253700,
      "headline": "Gene-Editing Stocks Gain on LLY-VERV Deal Announcement",
      "id": 135370758,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.",
      "url": "https://finnhub.io/api/news?id=0e5e497a13ebc0a5849ce40d27b13c4116ceec96870181d53d6d43407edb73c5"
    }
  },
  {
    "ts": null,
    "headline": "IHE: Healthcare Dashboard For June",
    "summary": "This is our monthly dashboard series on Healthcare and Pharma stocks. Read the full analysis here, and which 10 healthcare stocks were cheaper than their peers in June 2025.",
    "url": "https://finnhub.io/api/news?id=5bd3d37037c925aa23d9d9138ebe7c3a09ec14b7fca953591a7be9042018cd10",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750253083,
      "headline": "IHE: Healthcare Dashboard For June",
      "id": 135370933,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/901284104/image_901284104.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "This is our monthly dashboard series on Healthcare and Pharma stocks. Read the full analysis here, and which 10 healthcare stocks were cheaper than their peers in June 2025.",
      "url": "https://finnhub.io/api/news?id=5bd3d37037c925aa23d9d9138ebe7c3a09ec14b7fca953591a7be9042018cd10"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?",
    "summary": "Novo Nordisk has been actively pursuing licensing deals over the past six months.  There are other good reasons to consider investing in Novo Nordisk right now.  It wasn't so long ago that Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, seemed to be firing on all cylinders.",
    "url": "https://finnhub.io/api/news?id=ae1782533e3940cd0ab294e002f52abb465c9788cb2d0df39d2b564eb6d3b07c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750247100,
      "headline": "Novo Nordisk Just Improved Its Weight-Management Pipeline: Is the Stock a Buy?",
      "id": 135358097,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk has been actively pursuing licensing deals over the past six months.  There are other good reasons to consider investing in Novo Nordisk right now.  It wasn't so long ago that Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, seemed to be firing on all cylinders.",
      "url": "https://finnhub.io/api/news?id=ae1782533e3940cd0ab294e002f52abb465c9788cb2d0df39d2b564eb6d3b07c"
    }
  },
  {
    "ts": null,
    "headline": "US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list",
    "summary": "A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's blockbuster weight-loss drugs Ozempic and Wegovy, upholding the U.S. Food and...",
    "url": "https://finnhub.io/api/news?id=d525349c48d760687b8cc4b2d06f350c95cc909201d43e002e61075a13878481",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750244470,
      "headline": "US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list",
      "id": 135372761,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's blockbuster weight-loss drugs Ozempic and Wegovy, upholding the U.S. Food and...",
      "url": "https://finnhub.io/api/news?id=d525349c48d760687b8cc4b2d06f350c95cc909201d43e002e61075a13878481"
    }
  },
  {
    "ts": null,
    "headline": "Fat, not muscle: Drugmakers in race for next weight-loss breakthrough",
    "summary": "Current weight-loss methods such aslifestyle changes, surgery, and popular therapies like NovoNordisk's Wegovy and Eli Lilly'sZepbound result in both fat and muscle loss that can increasethe risk...",
    "url": "https://finnhub.io/api/news?id=2aa5546a7f1db29ccb44235ded216c57a1d848bde633c4ccf77890cd178d05a3",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750243342,
      "headline": "Fat, not muscle: Drugmakers in race for next weight-loss breakthrough",
      "id": 135358844,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Current weight-loss methods such aslifestyle changes, surgery, and popular therapies like NovoNordisk's Wegovy and Eli Lilly'sZepbound result in both fat and muscle loss that can increasethe risk...",
      "url": "https://finnhub.io/api/news?id=2aa5546a7f1db29ccb44235ded216c57a1d848bde633c4ccf77890cd178d05a3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Strikes Back Against Pharmacy Compounders And Telehealth Platforms",
    "summary": "Highlights ...",
    "url": "https://finnhub.io/api/news?id=c471888c0b6a9f2796eacf8d9f3ac3580f1ec0d71cfc0b1c189e81a258c464c3",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750241410,
      "headline": "Eli Lilly Strikes Back Against Pharmacy Compounders And Telehealth Platforms",
      "id": 135356602,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Highlights ...",
      "url": "https://finnhub.io/api/news?id=c471888c0b6a9f2796eacf8d9f3ac3580f1ec0d71cfc0b1c189e81a258c464c3"
    }
  },
  {
    "ts": null,
    "headline": "Move Over Hims & Hers Health: This Insurance Business Could Be the Next Monster Healthcare Stock (Hint: It's Not UnitedHealth)",
    "summary": "Hims & Hers Health shares rocketed higher over the last year, rewarding investors.",
    "url": "https://finnhub.io/api/news?id=8645a39cfccb91d25054cf6b9af779bd36c85a38e2cd67f28d569e6ebe5599d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750234800,
      "headline": "Move Over Hims & Hers Health: This Insurance Business Could Be the Next Monster Healthcare Stock (Hint: It's Not UnitedHealth)",
      "id": 135349674,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Hims & Hers Health shares rocketed higher over the last year, rewarding investors.",
      "url": "https://finnhub.io/api/news?id=8645a39cfccb91d25054cf6b9af779bd36c85a38e2cd67f28d569e6ebe5599d2"
    }
  },
  {
    "ts": null,
    "headline": "Adam Parker of Trivariate Research Recommends Eli Lilly’s Dividend as a Defensive Play",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of Best Dividend Stocks to Buy for Dependable Dividend Growth. According to Adam Parker, founder of Trivariate Research, investors aiming for a defensive approach might want to look at select dividend-paying stocks. In a note dated June 8, Parker mentioned that while many institutional investors still expect the […]",
    "url": "https://finnhub.io/api/news?id=a76242bfd4c23a518fc149cd11d4ef4ec3dad3a0053480892333281806f19559",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750232221,
      "headline": "Adam Parker of Trivariate Research Recommends Eli Lilly’s Dividend as a Defensive Play",
      "id": 135349435,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of Best Dividend Stocks to Buy for Dependable Dividend Growth. According to Adam Parker, founder of Trivariate Research, investors aiming for a defensive approach might want to look at select dividend-paying stocks. In a note dated June 8, Parker mentioned that while many institutional investors still expect the […]",
      "url": "https://finnhub.io/api/news?id=a76242bfd4c23a518fc149cd11d4ef4ec3dad3a0053480892333281806f19559"
    }
  },
  {
    "ts": null,
    "headline": "Health Rounds: Weight-loss surgery more effective than drugs in real world study",
    "summary": "Bariatric surgeries led to aboutfive-times more weight loss than weekly injections of popularGLP-1 drugs, according to data from a real-world comparisonstudy presented on Tuesday at the American...",
    "url": "https://finnhub.io/api/news?id=5f092b74d9eef3c2ddfc25aa077561ced4d218b896339e8f447e5da66c75b8fd",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750230093,
      "headline": "Health Rounds: Weight-loss surgery more effective than drugs in real world study",
      "id": 135352620,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Bariatric surgeries led to aboutfive-times more weight loss than weekly injections of popularGLP-1 drugs, according to data from a real-world comparisonstudy presented on Tuesday at the American...",
      "url": "https://finnhub.io/api/news?id=5f092b74d9eef3c2ddfc25aa077561ced4d218b896339e8f447e5da66c75b8fd"
    }
  }
]